Simplified Cardiovascular Management Study (SimCard)

This study is not yet open for participant recruitment.
Verified December 2011 by The George Institute for Global Health, China
Sponsor:
Collaborator:
Information provided by (Responsible Party):
The George Institute for Global Health, China
ClinicalTrials.gov Identifier:
NCT01503814
First received: December 30, 2011
Last updated: January 3, 2012
Last verified: December 2011
  Purpose

The goal of this study is to develop, pilot test, and evaluate a highly simplified but guideline-based program for cardiovascular management for application in resource-scarce settings. The study aims to assess the effects of implementing a simple low-cost cardiovascular management program for high-risk individuals, delivered by primary care providers (PCPs) or community health workers (CHWs), on the proportion of patients appropriately treated with diuretics as well as a number of secondary outcomes in resource-scarce Tibet, China.


Condition Intervention
Cardiovascular Disease
Other: Simplified cardiovascular disease management

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Simplified Cardiovascular Management Study: A Cluster-Randomized Trial to Evaluate the Effects of a Simplified Cardiovascular Management Program in Tibet, China

Resource links provided by NLM:


Further study details as provided by The George Institute for Global Health, China:

Primary Outcome Measures:
  • Net Difference in Proportion Treated with Low-dose Diuretics [ Time Frame: baseline and at one year ] [ Designated as safety issue: No ]
    The primary outcome will be the net differences between the changes in the proportion of high-risk individuals treated with low-dose diuretics pre-and-post intervention between intervention and control villages. The outcome measure will be assessed via a questionnaire that will ask about low-dose diuretics usage that will be administered at baseline and then again following the intervention period at around one year.


Secondary Outcome Measures:
  • Net Difference from Baseline in Mean Blood Pressure [ Time Frame: baseline and at one year ] [ Designated as safety issue: No ]
    The net difference in mean post-intervention blood pressure changes of high-risk patients from baseline between intervention and control villages will be measured. This outcome measure will be taken at baseline and then again following the intervention period at around one year using a standardized electronic blood pressure monitor. Each subject's blood pressure will be taken twice at different time points within the same visit for the baseline measurement and one year follow-up measurement.


Estimated Enrollment: 1000
Study Start Date: January 2012
Estimated Study Completion Date: January 2013
Estimated Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control (Usual Care)
Experimental: Intervention
Use of a simplified guideline-based CVD prevention and management scheme by village doctors targeting high risk individuals focusing on a"2+2"model: 2 therapeutic lifestyle recommendations (smoking cessation and salt consumption reduction) plus prescription of 2 low-cost drugs (aspirin and low-dose diuretics) when applicable
Other: Simplified cardiovascular disease management

This study is a complex pragmatic trial.The intervention includes a "package" of 4 main established measures for cardiovascular prevention and management:

2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption

2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)


Detailed Description:

Cardiovascular disease (CVD) is the leading cause of morbidity, mortality, and disability in not only developed, but also developing countries. There are well-established interventions such as lifestyle modification and drug therapies, i.e., aspirin and low-dose diuretics, that along with their consistent use, can help alleviate these burdens if the practicalities of how to deliver such care to large numbers in resource-poor settings at low cost can be resolved. One particular cost-effective approach for secondary prevention of CVD is to identify and manage individuals at high CVD risk in order to prevent or delay events. This approach has been tested in the rural Andhra Pradesh Cardiovascular Prevention Study in India and is currently being implemented in rural areas of northern China in the China Rural Health Initiative funded by NHLBI.

This project aims to address the highly prevalent problem of CVD in even more remote and poor areas of China that have received only minimal attention so far, specifically Tibet, China. This pilot project will be a cluster-randomized controlled interventional trial that will include a total of 20 villages in 8 townships in Gongbujiangda County, Tibet and will last for one year. The villages will be randomized to receive either the intervention package (10 villages) or usual care (10 villages). At baseline, village-wide screenings will be done to identify high-risk individuals in the selected villages who will then be followed throughout the study to about one year.

The interventional model will make use of a highly simplified cardiovascular disease management plan targeting lifestyle modification and utilization of basic drug regimens to help overcome the barriers in prevention and management of CVD in these areas with extremely limited economic and natural resources, minimal public awareness to the problem, and a lack of trained healthcare professionals.

Electronic blood pressure monitors will be used in all villages to measure the blood pressures of these individuals. However accuracy of the electronic blood pressure monitor measurements needs to be considered due to Tibet's high altitude. A study to validate and calibrate the selected blood pressure monitor model in both plains and high altitude areas will thus be undertaken using the validation procedure published by the European Society of Hypertension (ESH) to ensure accuracy.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Age is equal or older than 40 years old AND the subject has a self-reported history of ANY of the following diseases:

  • CVD OR
  • Diabetes OR
  • Stroke (including both Ischemic Stroke and Haemorrhagic Stroke) OR
  • Measured systolic blood pressure is equal or greater than 160mmHg at two different time points in the same day during the baseline survey.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01503814

Contacts
Contact: Lijing Yan, PhD +86 82800577 ext 309 ylijing@georgeinstitute.org.cn
Contact: Maoyi Tian, PhD +86 82800577 ext 303 tmaoyi@georgeinstitute.org.cn

Locations
China, Tibet Autonomous Region
Gongbujiangda County Not yet recruiting
Linzhi, Tibet Autonomous Region, China, 850000
Contact: Zhong Liu, MD     13989096563     896568978@qq.com    
Sponsors and Collaborators
The George Institute for Global Health, China
Investigators
Principal Investigator: Lijing Yan, PhD The George Institute, China (Beijing, CN)
  More Information

Publications:
Responsible Party: The George Institute for Global Health, China
ClinicalTrials.gov Identifier: NCT01503814     History of Changes
Other Study ID Numbers: 03COE-RA02, HHSN268200900027C
Study First Received: December 30, 2011
Last Updated: January 3, 2012
Health Authority: China: Ethics Committee
United States: Institutional Review Board

Keywords provided by The George Institute for Global Health, China:
hypertension
primary care
cardiovascular disease prevention
high cardiovascular risk
diuretics
aspirin
smoking cessation
salt reduction
Tibet

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on June 17, 2013